Craft

Urovant Sciences

Stock Price

$16.2

2021-04-01

Market Capitalization

$531.8 M

2021-04-01

Urovant Sciences Summary

Company Summary

Overview
Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. The Company's lead therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Type
Public
Status
Active
Founded
2016
HQ
Irvine, CA, US | view all locations
Website
https://urovant.com/
Cybersecurity rating
Sectors

Key People

  • Cornelia Haag-Molkenteller

    Cornelia Haag-Molkenteller, EVP & Chief Medical Officer

    • Walt Johnston

      Walt Johnston, EVP, Commercial

      • Ryan Card

        Ryan Card, EVP & General Counsel

        • Kenton Stewart

          Kenton Stewart, EVP, Market Access

          Operating MetricsView all

          Phase III Patients Enrolled

          1.4K

          Q1, 2019

          LocationsView all

          2 locations detected

          • Irvine, CA HQ

            United States

            5281 California Ave #100

          • Basel, BS

            Switzerland

            Viaduktstrasse 8

          Urovant Sciences Financials

          Summary Financials

          Net income (FY, 2020)
          ($146.7M)
          Cash (FY, 2020)
          $51.4M
          Enterprise value
          $483.8M

          Footer menu